Skip to content

Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy

Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy: A Randomized Tandem Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05018325
Enrollment
32
Registered
2021-08-24
Start date
2021-08-30
Completion date
2022-08-19
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer, Colorectal Cancer, Rectal Cancer

Brief summary

The investigators' null hypothesis is that a withdrawal time of 9 to 10 minutes is non-inferior to a withdrawal time of 12 minutes or greater. Thus, the goal of this tandem design trial is to compare the additional diagnostic yield (# of missed lesions) for withdrawal times exceeding 10 minutes for screening/surveillance colonoscopies. Although withdrawal times longer than the standard 6-minute recommendation have been shown to be beneficial, there is limited prospective evidence investigating the benefit or lack thereof for withdrawal times greater than 9-10 minutes.

Interventions

PROCEDUREColonoscopy with 6 minute withdrawal

Withdrawal time will be determined using a digital stopwatch by the nursing staff.

PROCEDUREColonoscopy 9 minute withdrawal

Withdrawal time will be determined using a digital stopwatch by the nursing staff.

PROCEDUREColonoscopy 12 minute withdrawal

Withdrawal time will be determined using a digital stopwatch by the nursing staff.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Must be between the ages of 18 and 75 years * Must be a patient undergoing screening or surveillance colonoscopy * Must be able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion criteria

* Inability to provide informed consent. * Personal history of colorectal cancer (CRC) * Personal history of colon surgery or colon resection * Personal history of Inflammatory bowel disease * Personal history of familial polyposis * Current pregnancy * Active GI bleeding * Colonoscopy exams where the cecum cannot be reached (randomization will occur after cecum is reached).

Design outcomes

Primary

MeasureTime frameDescription
Miss rate of polypsTime of colonoscopy (day 1)* Miss rate = missed polyps/missed polyps + polyps found during 1st exam * Polyps is defined as adenomas and sessile serrated adenomas (SSA)

Secondary

MeasureTime frameDescription
Miss rate of advanced adenomasTime of colonoscopy (day 1)* Miss rate = missed advanced adenomas/missed advanced adenomas + advanced adenomas found during 1st exam * Advanced adenoma defined as a polyp ≥ 10mm, adenomas with high-grade dysplasia or villous architecture, serrated lesions with dysplasia, or traditional serrated adenomas

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026